28/06/2021
Stay Informed and Healthy.....
IBOGA - A non-hallucinogenic psychedelic analogue with therapeutic potential
For thousands of years, the root bark of the tropical shrub Tabernanthe Iboga has been the basis of a tradition of initiation and healing in the forests of Western Equatorial Africa. It is used as a tool for contacting ancestors, engaging natural spirits and accessing other dimensions to get advice for healing and moral life management.
Anxiety, Depression, Addiction, and the Psychedelic Connection
Over the past several years, neuroscientists and mental health professionals have become intrigued with the potential of psychedelics to open people’s minds to healthy change and to combat mental illness. Ibogaine’s successes —as well as the successes of psilocybin and ketamine — suggest that psychedelics may one day be recognized as powerful medicines.
The psychedelic alkaloid ibogaine has anti-addictive properties in both humans and animals. Unlike most medications for the treatment of substance use disorders, anecdotal reports suggest that ibogaine has the potential to treat addiction to various substances, including opiates, alcohol and psychostimulants. The effects of ibogaine-like those of other psychedelic compounds-are long-lasting, which has been attributed to its ability to modify addiction-related neural circuitry through the activation of neurotrophic factor signalling.
Ibogaine is an extract of the naturally-growing African plant, iboga. A drug for medicinal use in humans is in development; clinical trials are anticipated.
In rodents, tabernanthalog was found to promote structural neural plasticity, reduce alcohol- and heroin-seeking behaviour, and produce antidepressant-like effects. This work demonstrates that, through careful chemical design, it is possible to modify a psychedelic compound to produce a safer, non-hallucinogenic variant that has therapeutic potential.
Ibogaine is an extract of the naturally-growing African plant, iboga. A drug for medicinal use in humans is in development; clinical trials are anticipated.
